Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
12,13-diHOME (12,13-dihydroxy-9Z-octadecenoic acid) is an endogenous lipokine derived from brown adipose tissue (BAT) that is significantly upregulated in response to cold exposure and exercise. It serves as a signaling molecule that mediates metabolic benefits, specifically by promoting the recruitment of macrophages to brown adipose tissue and enhancing fatty acid uptake in peripheral tissues like skeletal muscle. Recent research has identified that 12,13-diHOME signals through a specific, previously uncharacterized G protein-coupled receptor (GPCR) to drive these effects. The molecule is being investigated for its potential to treat metabolic disorders by modulating cell-cell communication within the adipose microenvironment and improving thermogenic function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 12,13-diHOME.